Zenith Technologies and GE Healthcare Life Sciences to Collaborate on Biopharmaceutical Manufacturing Deployment
As part of the partnership, Zenith Technologies’ methodologies, systems, and libraries will be offered as a service to GE Healthcare’s clients in bioprocessing.
Zenith Technologies and GE Healthcare’s Life Sciences business will collaborate on biopharmaceutical manufacturing deployment, according to an April 4, 2016 press announcement.
According to the press announcement, as part of the partnership, Zenith Technologies’ methodologies, systems, and libraries will be offered as a service to GE Healthcare’s clients in bioprocessing. The two companies will integrate process control systems, manufacturing execution system (MES) solutions, and other supporting technologies with GE Healthcare’s technologies and solutions for the biopharmaceutical manufacturing industry.
"The development of our KUBio modular manufacturing facilities and FlexFactory single-use manufacturing platform was fuelled by the need for customers to deploy biopharmaceutical manufacturing capacity more quickly and at a lower cost,” said Jan Makela, general manager at BioProcess GE Healthcare in a statement. “Implementing these advanced technology platforms requires automation expertise for which we partner with a number of world class companies.”
Source: Zenith Technologies
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
